Stay updated with breaking news from அமிகஸ் பொம்பே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Amicus Therapeutics, inc (FOLD) Q2 2021 Earnings Call Transcript msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
MedCity News Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter. Shares1
Amicus Therapeutics aims to position its experimental Pompe disease treatment as the new standard of care, supplanting a therapy from Sanofi. But securing approval will require explaining to regulators why they should look past the treatment’s failure to achieve the main goal of a pivotal study. The main goal of the Phase 3 study testing the Amicus drug, AT-GAA, was to measure how much further, on average, patients could walk in a six-minute test after 52 weeks of treatment. Pompe patients have an inherited enzyme deficiency that leads to a progressive weakening of their muscles. ....